| ImmunoGen, Inc. F3Q10 (Qtr End 03/31/10) Earnings Call Transcript ImmunoGen, Inc. (IMGN)F3Q10 (Qtr End 03/31/10) Earnings Call TranscriptApril 29, 2009 4:30 pm ETComplete Story » seekingalpha.com |
Cord Blood America Names Managing Director of Its New Stem Cell Company in Germany (PR Newswire) Cord Blood America, Inc. is pleased to announce that Thomas Kolzau, Hamburg, Germany, an executive with a strong record of success in the medical, life sciences and bio/pharma industries, has been appointed Managing Director of Cord Blood America's 51 percent owned stellacure GmbH, the third largest cord blood banking service in Germany. us.rd.yahoo.com |
Genoptix, Inc. to Announce Second Quarter 2010 Financial Results (PR Newswire) Genoptix, Inc. , a specialized laboratory services provider, announced today that it expects to report its financial results for the second quarter 2010 after closing of the NASDAQ Global Select Market on Thursday, July 29, 2010. us.rd.yahoo.com |
Wyeth's Ghost in the Medical Machine The Burrill Report submits: A study of documents unsealed in litigation against the pharmaceutical company Wyeth (WYE) show the drug giant paid ghostwriters to insert marketing messages into articles in medical journals, according to researchers at Georgetown University Medical Center in a study published in PLoS Medicine. In July 2009, PLoS Medicine, represented by the public interest law firm Public Justice, and The New York Times, acted as interveners in litigation against menopausal hormone manufacturers by 14,000 plaintiffs whose claims related to the development of breast cancer while taking the hormone therapy Prempro. This resulted in a U.S. federal court decision to release approximately 1,500 documents to the public.Complete Story » seekingalpha.com |
Array Biopharma: A Wall Street Anomaly Ohad Hammer submits:Array’s (ARRY) shares keep on fluctuating in the $2.5-$3.5 range, relatively unchanged from the beginning of 2010. It seems that the market is having trouble assessing the real value of the company and its pipeline, which includes 13 (!) drugs in clinical trials. With a market cap of ~$170M, the market puts an average price tag of $13M per asset, a ridiculously low valuation (assuming no value is assigned to the company’s discovery platform). The company’s long term debt (due in 2014) could be partially blamed for this anomaly, but the problem seems to be more related to the company’s business model. The good news is that during the next year the company is looking at multiple events that might change the way Wall Street views Array.Array’s strength is also its Achilles’ heel: It has too many things going on and the majority of the programs are in early stage development without a clear and fast route to market. In that sense, the situation is very similar to that of Exelixis (EXEL), as I discussed two months ago. In order to get a realistic price tag from Wall Street, both companies must come up with a “killer app”, an indication that represents high probability of success, short time to market and a commercial opportunity of at least $100M. Although Array is not there yet, it could become highly attractive due to three trends: Out- licensing of wholly owned agents, maturation of partnered and proprietary programs and attrition.Maturing pipelineComplete Story » seekingalpha.com |